Fresenius SE Total Current Liabilities 2016-2024 | FSNUY
Fresenius SE total current liabilities from 2016 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
- Fresenius SE total current liabilities for the quarter ending June 30, 2024 were $9.957B, a 43.13% decline year-over-year.
- Fresenius SE total current liabilities for 2023 were $10.098B, a 29.83% decline from 2022.
- Fresenius SE total current liabilities for 2022 were $14.39B, a 19.25% decline from 2021.
- Fresenius SE total current liabilities for 2021 were $17.82B, a 18.04% increase from 2020.
Fresenius SE Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$10,098 |
| 2022 |
$14,390 |
| 2021 |
$17,820 |
| 2020 |
$15,097 |
| 2019 |
$15,550 |
| 2018 |
$15,678 |
| 2017 |
$12,055 |
| 2016 |
$9,455 |
| 2015 |
$8,227 |
Fresenius SE Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$9,957 |
| 2024-03-31 |
$9,094 |
| 2023-12-31 |
$10,098 |
| 2023-09-30 |
$31,769 |
| 2023-06-30 |
$17,509 |
| 2023-03-31 |
$17,087 |
| 2022-12-31 |
$14,390 |
| 2022-09-30 |
$14,969 |
| 2022-06-30 |
$15,218 |
| 2022-03-31 |
$388 |
| 2021-12-31 |
$17,820 |
| 2021-09-30 |
$18,103 |
| 2021-06-30 |
$18,319 |
| 2021-03-31 |
$19,226 |
| 2020-12-31 |
$15,097 |
| 2020-09-30 |
$16,197 |
| 2020-06-30 |
$17,004 |
| 2020-03-31 |
$17,640 |
| 2019-12-31 |
$15,550 |
| 2019-09-30 |
$15,323 |
| 2019-06-30 |
$15,449 |
| 2019-03-31 |
$15,529 |
| 2018-12-31 |
$15,678 |
| 2018-09-30 |
$15,459 |
| 2018-06-30 |
$14,458 |
| 2018-03-31 |
$13,826 |
| 2017-12-31 |
$12,055 |
| 2017-09-30 |
$12,513 |
| 2017-06-30 |
$11,405 |
| 2017-03-31 |
$10,853 |
| 2016-12-31 |
$9,455 |
| 2016-09-30 |
$9,351 |
| 2016-06-30 |
$9,101 |
| 2016-03-31 |
$8,163 |
| 2015-12-31 |
$8,227 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.704B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
